Ocuphire Pharma has announced the acquisition of Opus Genetics to create a biotech company dedicated to gene therapy ...

Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see ...

Canaccord lowered the firm’s price target on Ocuphire Pharma (OCUP) to $10 from $18 and keeps a Buy rating on the shares. The firm noted ...

Ocuphire Pharma ( (OCUP) ) just unveiled an update. Ocuphire Pharma has acquired Opus Genetics in an all-stock merger, ...

H.C. Wainwright placed the firm’s Buy rating on Ocuphire Pharma (OCUP) under review saying the acquisition of Opus Genetics starts a new chapter. Published first on TheFly – the ultimate source for ...

Ocuphire Pharma acquires Opus Genetics, expanding its IRD gene therapy pipeline. The renamed company, Opus Genetics, will trade under "IRD" by late024.

The company will seek a strategic partner to continue development of APX3330, an oral small-molecule inhibitor of Ref-1 for ...

The eye drop maker Ocuphire Pharma and startup Opus Genetics are merging in an all-stock deal, the companies told Endpoints ...

In the transaction, Ocuphire will issue 5.2 million shares of its common stock and 14.1 thousand shares of its convertible preferred stock to existing stockholders of Opus Genetics. Ocuphire insiders ...

Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies ...

FARMINGTON HILLS, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing ...